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Abstract
We have previously shown that endothelial cell matrix metalloprotease 12 (MMP12) and pentraxin 3 (PTX3) over-
production is the main alteration accounting for reduced proneness to angiogenesis in systemic sclerosis (SSc).
On this basis, we stably transfected MMP12 and PTX3 in two breast cancer cell lines expressing very low amounts
of the target molecules when compared with normal breast epithelial cells, relying on the hypothesis that anti-
angiogenic molecules released by cancer cells could confer an SSc-like antiangiogenic pattern on target endothelial
cells. In Matrigel Boyden chamber invasion and capillary morphogenesis studies, transfected clones reduced endo-
thelial cell invasion and capillary tube formation, which were abolished by tumor cell populations expressing both
molecules. The Matrigel sponge assay, performed in vivo in C57/BL6 mice by injecting aliquots of lyophilized cul-
ture medium of transfected clones, indicated a similar reduction in angiogenesis. Functional studies have shown that
endothelial cells treated with a culture medium of MMP12-expressing clones underwent cleavage of urokinase-type
plasminogen activator receptor domain 1 which is indispensable to angiogenesis. We did not observe angiostatin
production from plasminogen under the same experimental conditions. PTX3-overexpressing clones showed a power-
ful anti-fibroblast growth factor 2 (FGF2) activity in FGF2-dependent capillary morphogenesis. We have injected con-
trol and transfected clones into nude nu/nu (CD-1) BR mice to study the differential tumor growth pattern. We
observed a reduction of tumor growth in transfected clones, which was basically complete when clones expressing
bothmolecules were simultaneously injected. The extent of tumor necrosis suggested an antiangiogenesis-dependent
inhibition of tumor development.
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Introduction
When tumors undergo the “angiogenic switch,” an expanding vascular
bed penetrates into cancerous growth [1–3]. Vessels supply oxygen and
nutrients to the tumor, even if a large part of malignant cells survive in a
state of hypoxia and nutrient starvation despite hypoxia-dependent
mechanisms aimed to promote vascular invasion [4]. Further, tumor
cells find a facilitated route for intravasation and metastatic spreading
[1]. Most human pathologies involving an altered angiogenesis, includ-
ing cancer, are characterized by excess angiogenesis. Conversely, in sys-
temic sclerosis (SSc), the sufferance of microvessels and the breakdown
of their patency lead to chronic tissue hypoxia and to capillary loss that
causes vital organ failure [5]. These features suggest an insufficient
angiogenic response [6], despite the tissue hypoxia that characterizes
the disease. Serum levels of vascular endothelial growth factor (VEGF)
and skin expression of both VEGF and its receptors VEGFR-1 and
VEGFR-2, as well as serum levels of fibroblast growth factor 2
(FGF2), result as dramatically upregulated throughout different stages
of SSc [7,8], but these features are not sufficient to trigger the angio-
genic process in hypoxic SSc tissues. Our comparative studies on
dermal microvascular endothelial cells (MVECs) of normal subjects
(N-MVEC) and SSc patients (SSc-MVEC) revealed that SSc-MVEC,
largely overexpressing proangiogenic factors, overproduce and secrete
two antiangiogenic molecules, namely, MMP12 and pentraxin 3
(PTX3) [9–11]. MMP12 is a metalloprotease that cleaves the domain 1
(D1) of urokinase-type plasminogen activator receptor (uPAR) [9],
thereby preventing uPAR binding of the uPA and uPAR interaction
with vitronectin and β2-integrin. Such interactions are essential for
the migration-degradation-adhesion phases of the endothelial cell
engaged in angiogenesis [9,10]. PTX3 [11,12] is a soluble pattern
recognition receptor with many functions, including inhibition of
FGF2-dependent angiogenesis [12,13]. On this basis, we have induced
breast cancer cells to overproduce MMP12 and PTX3, with the aim to
control tumor-dependent angiogenesis. Transfection of malignant cells
with either one of the two molecules resulted into a striking inhibition
of endothelial cell proneness to develop in vitro angiogenesis and of
tumor angiogenesis in vivo, which were abolished by the cumulative
effect of tumor cell populations expressing both molecules.
Materials and Methods
Cell Lines
Human microvascular endothelial cells (MVECs) were isolated from
skin biopsies of the hands in six healthy patients undergoing surgery for
traumatic events at the hands, as reported [9–11], and were maintained
in complete endothelial cell growth medium as described [9]. The study
was approved by the local ethical committee, and a written informed
consent form was obtained from each subject enrolled. Normal breast
ductal epithelial cells (line HB2), provided by Prof. Ida Pucci-Minafra
(Palermo, Italy), were grown as previously described [14]. Human
mammary carcinoma cell lines MCF-7 and MDA-MB-231, purchased
from American Type Culture Collection (Manassas, VA), were grown
in RPMI-1640 (Euroclone, Milano, Italy), added with 2 mM gluta-
mine, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 10% fetal
bovine serum (FBS; Euroclone).
Detection of Transcripts by Reverse Transcription–Polymerase
Chain Reaction
The expression of MMP12 and PTX3 genes was measured by reverse
transcription–polymerase chain reaction (PCR) assay as described [9,10].
PCR was performed in a thermocycler, and the reaction products were
analyzed by electrophoresis in 1% agarose gel containing ethidium
bromide followed by photography under ultraviolet illumination using
Polaroid positive/negative instant films (Polaroid Italia SpA, Varese, Italy),
as reported elsewhere [9]. Primers for MMP12, PTX3, and GAPDH,
cycling conditions, and size of the final products are reported in Table 1.
MMP12 and PTX3 Stable Transfection
MCF-7 andMDA-MB-231 cells were stably transfected with human
MMP12 or PTX3 genes obtained by retrotranscription. One microgram
of RNAwas extracted fromHeLa and PCR-amplified by specific primers
for MMP12 and PTX3. Reverse primers contained in the 3′ the se-
quence corresponding to the eight amino acids of the FLAG. The for-
ward and reverse primers for each gene are reported in Table 1. The
PCR fragments containing the entire ORF of MMP12 and PTX3
were cloned in XhoI and KpnI sites of pCDNA3.1+ vector, carrying
the G418 resistance sequence (Invitrogen Srl, Milano, Italy), to obtain
the pCDNA3.1+MMP12-FLAGand pCDNA3.1+PTX3-FLAGexpres-
sion vectors. MCF-7 andMDA-MB-231 (7 × 106) cells were transfected
by DharmaFECT reagent (Invitrogen) as described in the instructions
of the manufacturer, with 3.4 μg of pCDNA3.1+MMP12-FLAG,
pCDNA3.1+PTX3-FLAG, and pCDNA3.1+ empty vector, respectively,
and analyzed for expression 48 hours after transfection. The medium
containing the MMP12- or PTX3-FLAG was immunoprecipitated by
EZview Red ANTI-FLAG M2 Affinity Gel (Sigma, St Louis, MO)
and analyzed by immunorevelation using the anti-FLAG monoclonal
antibody (mAb; Sigma). The stable clones were obtained by selection
of transfected cells withG418 (800μg/ml; Sigma) administered 48hours
after transfection. The G418-resistant clones were isolated and analyzed
as described previously for the flagged protein expression levels.
In Vitro Parameters of Angiogenesis
Invasion assay. The Boyden chamber assay, where upper and lower
wells were separated by a porous membrane coated with Matrigel,
Table 1. Sequences of Primers.
A) Primers forRetrotranscription of Specific Sequences ofMMP12 andPTX3 to be InsertedwithinVectors
MMP12
Forward: ATG CGG TAC CAT GGG GAA GTT TCT TCT AAT A
Reverse: ATG CCT CGA GCT ATT TAT CGT CAT CGT CTT TGT AGT AAC CAA
ACC AGC TAT TGC TT
PTX3
Forward: TAC CGT CAT GGG GCA TCT CCT TGC GAT TCT
Reverse: ACG CTC GAG CTA TTT ATC GTC ATC GTC TTT GTA GTC TGA AAC
ATA CTG AGC TCC TCC A
B) Primers for Evaluation of Expression Pattern of MMP12 and PTX3
Primers Sequence Size (bp) Cycling Profile
MMP12 Forward: CCA CTG CTT CTG
GAG CTC TT
450 94°C, 45 sec
58°C, 45 sec




PTX3 Forward: GTG GGT GGA GAG
GAG AAC AA
400 94°C, 1 min
53°C, 1 min




GAPDH Forward: CCA CCC ATG GCA
AAT TCC ATG GCA
598 94°C, 1 min
56°C, 1 min
Reverse: TCT AGA CGG CAG
GTC AGG TCC ACC
72°C, 1 min
35 cycles total
Neoplasia Vol. 11, No. 10, 2009 PTX3 and MMP12 in Tumor Angiogenesis Margheri et al. 1107
was used to evaluate cell invasion as described [9,15]. A total of 8 × 103
MVECs were placed in the upper chamber for each point in cul-
ture medium added with 2% fetal calf serum. Control or transfected
cells were placed in the lower compartment, and migration was allowed
to occur for 6 hours at 37°C in 5% CO2. Mobilization was measured
by counting the number of cells moving across the filter. Each point
was performed in triplicate. Migration was expressed as the mean per-
centage of basal response ± SEM.
Capillary morphogenesis assay. Matrigel (0.5 ml; 10-12mg/ml) was
pipetted into 13-mm tissue culture wells and polymerized for 30minutes
to 1 hour at 37°C as previously described [9]. MVECs were plated (60 ×
103/ml) in endothelial cell growthmedium [9]. Capillarymorphogenesis
was recorded after 6 and 24 hours with an inverted microscope (Leitz
DM-IRB, Leico Microsystem Srl, Milano, Italy) equipped with CCD
optics and a digital analysis system. Results were quantified at 6 hours
by measuring the percent field occupancy of capillary projections. Six
to nine photographic fields from three plates were scanned for each point.
Western Blot Analysis
Cell lysates were obtained, processed, and blotted as described [9].
The primary antibodies used were as follows: anti-MMP12 (1 mg/ml,
1:500, catalog no. AB19051; Chemicon International, Temecula, CA),
anti-PTX3 (1 mg/ml, 1:500, catalog no. ALX-804-463; Alexis Bio-
chemicals Axxora, LLC, San Diego, CA), anti-FLAG (10 μg/ml,
1:5000, catalog no. F3165; Sigma), and anti–uPAR-D1 (500 μg/ml,
1:400, catalog no. 3931; American Diagnostica, Stamford, CT). The
same procedure was used for detection of MMP12 and PTX3 after
immunoprecipitation of flagged proteins from culture medium per-
formed according to the instructions of the manufacturer. After incu-
bation with horseradish peroxidase–conjugated donkey antimouse or
antirabbit immunoglobulin G (IgG; 1:5000) for 1 hour (AmershamBio-
science, GEHealthcare Europe,Milano, Italy), PTX3-antibody immune
complexes were detected with the ECL Detection System (Amersham
Bioscience). MMP12-antibody and Flag protein-antibody complexes
were revealed by an Odyssey Infrared Imaging System, using IRDye
800 CW goat antimouse IgG (1:12,000, cat. FE30926220; LI-COR
Biosciences, M-Medical, Milano, Italy) and Alexa Fluor 680 goat anti-
rabbit IgG (1:12,000, cat. A21076; Invitrogen) as fluorescent secondary
antibodies according to the instructions provided by the manufacturers.
Preparation of Conditioned Medium
Once at semiconfluence in T75 flasks, selected clones were washed
with PBS and maintained 72 hours in 10-ml serum-free culture me-
dium. The medium was then subjected to dialysis against 2000 ml
of distilled H2O for three times and lyophilized. Each lyophilized
sample was reconstituted in 200 μl of distilled water and used for the
Matrigel sponge assay.
Angiostatin Production
Ten milliliters of serum-free conditioned medium (CM) was prepared
as described previously and reconstituted in 200 μl of distilled water. Re-
constituted samples were incubated overnight at 37°C with plasminogen
(final concentration, 10 μg/ml) [16]. Angiostatin production was evalu-
ated by Western blot analysis of samples with antiangiostatin antibodies.
Matrigel Sponge Assay
Aliquots of 50 μl of reconstituted CM, containing 50 U/ml heparin,
were added to unpolymerized Matrigel at 4°C at a final volume of
0.6 ml. The Matrigel suspension was injected subcutaneously into
the flanks of C57/BL6 male mice (Charles River, Calco [Lecco], Italy)
using a cold syringe. At body temperature, the Matrigel polymerizes to
a solid gel, which becomes vascularized within 4 days in response to
angiogenic substances. Pellets were removed, photographed, minced,
Figure 1. Expression of MMP12 and PTX3 in MVECs, in breast normal cells, and carcinoma cells and capillary morphogenesis activity of
their CM. (A) Semiquantitative PCR of MMP12 and PTX3 complementary DNA in the indicated cells. Numbers on the left indicate the
size of PCR products in base pairs (bp). GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase. (B) Constitutive capillary morpho-
genesis activity of normal and breast epithelial cells (HB2) and of breast cancer cells at 6 hours after seeding. Pictures show the results of
a typical experiment of three experiments performed in triplicate. Numbers on the lower right side of each picture indicate the percent
field occupancy of capillary plexus as described in the Materials and Methods section. Quantification was performed only at 6 hours after
seeding and was obtained by scanning of six to nine photographic fields for each condition.
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and diluted in water to measure the hemoglobin content with a Drabkin
reagent kit (Sigma).
In Vivo Tumor Growth and Histology
Breast tumors were obtained by subcutaneous injection of 2.5 ×
106 MDA cells or 4 × 106 MCF-7 cells transfected with various plas-
mids, mixed with liquidMatrigel (final volume, 300 μl), in the flanks of
6-week-old nude nu/nu (CD-1) BR mice (Charles River). Four mice
were treated with empty plasmid-transfected cells, four mice with cells
encoding MMP12 (pMMP12), and four mice with cells encoding
PTX3 (pPTX3). The last four mice were inoculated with cell mix com-
posed of the two groups (pMMP12 + pPTX3). Tumor growth was
monitored at regular intervals by measuring two tumor diameters with
calipers and calculating the tumor volumes with the following formula:
length × width2 / 2. On day 23, animals were killed, and the tumors
were removed, weighed, and processed for histologic analysis performed
using the Azan-Mallory trichromic stain. The method couples a nuclear
staining obtained by carbofuchsine with a cytoplasm staining obtained
with Orange G, whereas connective tissue is revealed by aniline blue.
Control Matrigel samples stained from orange to orange-red. A single
tumor enucleated from each treated animal was paraffin-embedded,
and serial sections of each tumor were prepared and stained with the
Azan-Mallory stain. Three slides for each tumor were subjected to image
analysis by using a Leica DMR-DC200 light microscope equipped
with Leica DC200 digital imaging system (Leica Camera AG, Solms,
Germany). After examining of three to six fields/slide, we determined
the percentage of tumor cells within the tumor mass compared with
Matrigel and necrosis.
Statistical Analysis
Results are expressed as means ± SD for (n) experiments. Multi-
ple comparisons were performed by the Student-Newman-Keuls test
after demonstration of significant differences among medians by non-
parametric variance analysis according to Kruskal-Wallis.
Figure 2. Stable transfection of breast carcinoma cells withMMP12 and PTX3. (A and B)Western blot analysis ofMDA-MB-231 and ofMCF-7
cells, respectively, to identify transfected clones. Each panel shows Western blot analysis for PTX3 and MMP12 expressed by transfected
clones, identified either with anti-PTX3 and anti-MMP12 mAbs or with anti-FLAG antibodies. pCDNA3+ clones are marked with numbers,
whereas pPTX3 and pMMP12 clones are indicated with capital letters. pPTX3 and pMMP12 clones selected on the basis of relevant protein
expression of the transfected plasmid are encircled. Numbers on the right indicate molecular weights expressed in kilodaltons.
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Results
Characterization of Target Molecules in Human Normal
and Breast Carcinoma Cells and Evaluation of Differential
Angiogenic Properties In Vitro
MMP12 and PTX3 expression was evaluated by reverse transcription–
PCR in two lines of mammary carcinoma cells (MCF-7 and MDA-
MB-231) and HB2 normal mammary epithelial cells. Figure 1A shows
that both breast carcinoma lines expressed lower amounts of MMP12
with respect to normal mammary cells. In particular, MMP12 was
strongly downregulated in MCF-7 cells. PTX3 expression exhibited a
similar pattern. CM-challenged capillary morphogenesis assay indicated
that breast carcinoma lines were more efficient than normal ones in stimu-
lating capillary-like tube formation of target MVEC (Figure 1B).
Stable Transfection of Breast Carcinoma Cells and Evaluation
of Target Proteins Expression
The MCF-7 and MDA-MB-231 lines were stably transfected with
human MMP12 or PTX3 genes obtained by retrotranscription. Fig-
ure 2, A and B, shows the results in MDA-MB-231 and MCF-7 breast
carcinoma cells, respectively. Western blot analysis of cell lysates of
pCDNA3+ and transfected cells with anti-FLAG, anti-PTX3, and anti-
MMP12 mAbs allowed us to identify several clones showing a high
Figure 3. MMP12- and PTX3-transfected breast carcinoma cells–dependent Matrigel invasion and capillary morphogenesis of MVEC.
(A) Upper part of the figure shows Matrigel invasion of MVEC added to the upper compartment of the migration chamber in the presence
of MCF-7 cells transfected with pMMP12 (clone G) and with pPTX3 (clone A). Results are the mean of three different experiments per-
formed in triplicate. Similar results were also obtained with MCF-7 clones B and D for pMMP12 and with MCF-7 clones D and G for pPTX3.
The lower part of the figure shows capillary morphogenesis at 6 hours with CM of MCF-7 clone G for pMMP12, and clone A for pPTX3.
Similar results were obtained with other MCF-7 clones. Pictures show the results of a typical experiment of three experiments performed
in triplicate. For quantification of capillary morphogenesis, refer to the legend of Figure 1. *P < .05, significantly different from control.
(B) Same experiments as in panel A performed by using transfected MDA-MB-231 clones. Results of Matrigel invasion obtained with MDA-
MB-231 clone H for pMMP12 and clone I for pPTX3 are shown. CM from the same clones was used in the capillary morphogenesis
experiments shown in the lower part of the figure. All other MDA clones gave similar results. The numbers of experimental replicas were
the same reported for panel A. Pictures show the results of a typical experiment of three experiments performed in triplicate. *P < .05,
significantly different from control.
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expression of the relevant molecules. Selected clones for each transfection
were indicated with capital roman letters (circled in the figures) and used
in vitro and in vivo to evaluate their angiogenic abilities compared with
control pCDNA3+ clones.
New Angiogenic Properties In Vitro Acquired by Breast
Cancer Cells after Transfection
Wemeasured in vitro angiogenesis by evaluating the ability of cells to
induce invasion and capillary morphogenesis of MVEC. Control or
Figure 4. Activity onMVEC capillary morphogenesis of transfected MDA clones in the presence or absence of FGF2. MVEC uPAR cleavage
and angiostatin production. (A) MVEC capillary morphogenesis in the conditions reported in the legend of each picture. In the experiments
shown in this panel, the MDA-MB-231 clones used were clone H for pMMP12 and clone E for pPTX3. Pictures show the results of a typical
experiment of three experiments performed in triplicate bFGF, basic fibroblast growth factor. For quantification, refer to the legend of Fig-
ure 1. *P< .05, significantly different from control. Similar results were obtainedwithMCF-7 clones (not shown). (B)Western blot analysis of
MVEC with uPAR anti-D1 mAb after incubating with CM from all the selected clones of pMMP12-transfected MDA-MB-231 breast carci-
noma cells. α-Tubulin indicates loading control. Numbers on the right indicate molecular weights expressed in kilodaltons. MCF-7 clones
gave similar results (not shown). (C) Western blot analysis of aliquots of pMMP12-transfectedMDA-MB-231 clones medium incubated with
standard plasminogen and probed with antiangiostatin mAb. Ten milliliters of CM from each clone was dialyzed against distilled water,
lyophilized, and reconstituted in 200 μl of distilled water. Reconstituted samples were incubated overnight at 37°C with plasminogen (final
concentration, 10 μg/ml). Aliquots containing 50 μg of proteins, showing similar Ponceau Red densitometric patterns, were applied to each
lane. The figure shows the results of a typical experiment of three different experiments that gave similar results (not shown). MCF-7 clones
gave similar results.
Neoplasia Vol. 11, No. 10, 2009 PTX3 and MMP12 in Tumor Angiogenesis Margheri et al. 1111
transfected cells were placed in the lower well of the Boyden cham-
ber (10 × 103 cells per well) to investigate their ability to stimulate
MVEC invasion of Matrigel-coated porous filters. As shown in the
upper part of Figure 3A, transfected MCF-7 (clone A-PTX3 and clone
G-MMP12) induced a decrease of MVEC invasion. The lower part
of the same figure shows capillary morphogenesis performed with
MVEC in the presence of CM of MCF-7 clone G for MMP12 and
clone A for PTX3. Similar results (not shown) were obtained with all
selected MCF-7 clones (the ones encircled in Figure 2B). Figure 3B
shows the results obtained in the same experiments performed with
transfected MDA-MB-231 in Matrigel invasion and capillary mor-
phogenesis (clone H for MMP12 and clone I for PTX3). Similar re-
sults (not shown) were obtained with all selected MDA-MB-231
clones (the ones encircled in Figure 2A). The treatment drastically
inhibited MVEC ability to invade Matrigel and to form capillary-
like tubes. Cell proliferation was also evaluated in both cell lines and
related clones. Growth kinetics of control, pCDNA3+, pMMP12,
and pPTX3 clones did not substantially differ within each cell line
(not shown).
Evidences of Anti-FGF2 Activity and of uPAR Cleavage of
PTX3 and MMP12 Clones
In these studies, we used MDA-MB-231 clone E-PTX3 and
clone H-MMP12 and MCF-7 clone A-PTX3 and clone G-MMP12.
Figure 4A shows the results obtained with MDA clones. Whereas
exogenous addition of FGF2 (50 ng/ml) increased MVEC capillary
morphogenesis of both control (subpanel e compared with subpanel a)
and pCDNA3+-transfected MDA cells (subpanel f compared with
subpanel b), CM of PTX3-transfected MDA cells reduced MVEC
capillary morphogenesis with respect to both control (subpanel d com-
pared with subpanel a) untreated and pCDNA3+-transfected MDA
cells (subpanel d compared with subpanel b). An FGF2-dependent in-
crease of capillary morphogenesis (subpanels e and f ) was completely
reverted when FGF2 was added to CM of PTX3-transfected MDA
cells (subpanel h). These data are in agreement with the reported anti-
FGF2 activity of PTX3 [13] and suggest that the antiangiogenic
activity of PTX3 produced by transfected MDA is related to FGF2
inhibition. Similarly, MMP12 transfection induced a decrease of capil-
lary morphogenesis either alone (subpanel c) or on addition of FGF2
(subpanel g). Mixed CM (a combination of CM from MMP12- and
PTX3-transfected MDA), produced a strong inhibition of MVEC
capillary morphogenesis under both control (subpanel i) and FGF2
stimulation conditions (subpanel k). MCF-7 clones gave similar results
(not shown).
Anti-uPAR D1 mAb, which recognizes the three-domain native form
of uPAR [9,10], indicated a striking decrease of uPAR-D1 in MVEC
incubated with MDA clones producing high amounts of MMP12
(Figure 4B), whereas a polyclonal antibody, which recognizes both native
and truncated uPAR, did not show any difference between control and
MMP12-transfected clones.
Angiostatin, previously shown in the blood of mice grafted with
melanoma cells overexpressing MMP12 [17], has been considered
the effector of the antiangiogenic activity of MMP12. We have eval-
uated angiostatin production from plasminogen exogenously added
to CM of MMP12-transfected MDA (clones C, F, H, I; Figure 4C ).
We did not reveal any angiostatin production, and similar results
were also obtained with MCF-7 clones overexpressing MMP12
(not shown).
Matrigel Sponge Assay
To measure in vivo angiogenesis, we performed a Matrigel sponge
assay. Vascularization was evaluated in samples recovered from in-
jected Matrigel sponges containing aliquots of 50 μl of reconstituted
CM from control (pCDNA3+ alone) and MMP12 or PTX3 clones
of MDA-MB-231 (Figure 5A) and MCF-7 cells (Figure 5B) in ad-
dition to heparin (50 U/ml). Groups of four to eight pellets were
Figure 5.Matrigel sponge assay (in vivo angiogenesis). Angiogenesis
in a Matrigel sponge assay by the addition of Matrigel containing
heparin (50 U/ml) and aliquots of 50 μl of reconstituted CM, evaluated
by hemoglobin (Hb) content. (A) Results obtained with MDA-321
CM. For PTX3, we used CM prepared from clone B (Figure 2A); for
MMP12, we used CM prepared from clone I (Figure 2A); the mix
was a CM composed of 50% clone B and 50% clone I. Graphs are
shown as mean ± SE; ***P < .001 (Student’s t test). At the bottom
of each column, a representative photograph, taken at the stereo-
microscope, of individual Matrigel sponges recovered at autopsy
for the corresponding condition is shown. Clone I for PTX3 and
clone H for MMP12 gave similar results (not shown). (B) Results ob-
tainedwithMCF-7CM. For PTX3,we usedCMprepared fromclone A
(Figure 2B); for MMP12, we used CM prepared from clone G
(Figure 2B); the mix was a CM composed of 50% clone A and 50%
clone G. Graphs are shown as mean ± SE; ***P < .001, *P < .05
(Student’s t test). At the bottom of each column, a representative
photograph, taken at the stereomicroscope, of individual Matrigel
sponges recovered at autopsy for the corresponding condition is
shown. Clone G for PTX3 and clone D forMMP12 gave similar results
(not shown).
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injected for each treatment. Individual Matrigel sponges were recovered
at autopsy 5 days after implants. Whereas angiogenesis was stimulated
by control cells culture medium, it was inhibited by both MMP12- and
PTX3-expressing clones, as shown also by decreases in hemoglobin con-
tent. The effect was particularly relevant when a mixture of media ob-
tained from MMP12- and PTX3-transfected clones was used.
Tumor Development in the nu/nu Mice
Figure 6 shows theMDA (A) andMCF-7 (B) growth curve and final
tumor size in nu/nu (CD-1) BR mice. Reduction of tumor volume was
observed with both MMP12- and PTX3-transfected clones. Injection
of mixed cell populations, each one expressing a single transfected gene
(MMP12 and PTX3), resulted into an almost complete impairment of
tumor growth as shown by histologic analysis of tumor samples stained
with Azan-Mallory stain (Figure 7). The Azan-Mallory stain allowed to
identify epithelial cells (red nuclei and pale red cytoplasm), Matrigel
(from orange to orange-red), and tissue necrosis (a few pale red nuclei
within a blue collagen large meshwork, which is the chief component of
the necrotic tissue). By the image analysis equipment described under
Materials and Methods, we determined the percentage of tumor cells
within the tumor mass. MDA-pCDNA3 cells represented 93.7 ± 8%
of the total tumor size, MDA-MMP12 cells represented 32.6 ± 6% of
the total tumor size, and MDA-PTX3 cells represented 84.2 ± 11% of
the total tumor size, whereas the mixture of MDA-MMP12/MDA-
PTX3 cells resulted into a real tumor cell burden representing only
13.5 ± 4% of the total tumor size. MCF-7 cells gave similar results
as shown in the lower graph of panel B in Figure 6.
Discussion
We have shown that overexpression of MMP12 and PTX3 by stable
transfection in human mammary carcinoma cells reduced their ability
to stimulate angiogenesis both in vitro and in vivo. The choice of the
two molecules to be overexpressed by cancer cells through transfection
of the relevant complementary DNA was based on previous demon-
strations of their antiangiogenic role in MVEC isolated from skin bi-
opsies of patients affected by the diffuse form of SSc [9–11], basically
Figure 6. Tumor growth in vivo. Breast tumors were obtained by subcutaneous injection of 2.5 × 106 MDA cells (A) and 4 × 106 MCF-7
cells (B) mixed with liquid Matrigel (final volume, 300 μl) in the flanks of 6-week-old nude nu/nu (CD-1) BR mice. MDA and MCF-7 cells
were transfected with different plasmid as shown. The 16 animals used for each cell line were treated as described in the Materials and
Methods section. Briefly, four mice were injected with control pCDNA3+ cells (MDA or MCF-7), four mice with a pPTX3 clone (clone I for
MDA and clone A for MCF-7), four mice with a pMMP12 clone (clone H for MDA and clone G for MCF-7), and four mice with a cell mix
of both clones of MDA and MCF-7. Tumor growth was monitored at regular intervals by measuring two tumor diameters with calipers
and calculating the tumor volumes with the following formula: length × width2 / 2. On day 23, the animals were killed, and the tumors
were removed, weighed, and fixed in formalin. On the basis of image analysis of Azan-Mallory–stained tumor slices, the percent amount
of cells over the whole mass recovered at autopsy (cell, Matrigel, and necrosis, when present) was calculated. Statistical analysis was
therefore performed only for the cellular content (see the lower graphs of panels A and B). Graphs are shown as mean ± SE; ***P <
.001, *P < .05 (Student’s t test).
Neoplasia Vol. 11, No. 10, 2009 PTX3 and MMP12 in Tumor Angiogenesis Margheri et al. 1113
relying on the working hypothesis that antiangiogenic molecules re-
leased by cancer cells could confer an SSc-like antiangiogenic pattern
on target MVEC. MMP12 released from stably transfected breast
cancer cells cleaved MVEC uPAR. uPAR cleavage-dependent decrease
of MVEC angiogenesis has to be related to the loss of the well-known
properties of native full-length uPAR to interact with integrins [18] as
well as to the parallel reduction of uPAR and integrins’ abilities to inter-
act with extracellular matrixmolecules [19,20]. Further, uPARD1 cleav-
age cancels uPA binding to uPAR, thereby eliminating uPAR-driven
pericellular proteolysis that enables endothelial cells to move within
tissues. Taken together, such new features result into the loss of MVEC
“grip-and-go” properties required to perform a complete angiogenesis
program. Antiangiogenic properties ofMMP12 transfection intomurine
melanoma cells, eventuating into a reduction of tumor growth in grafted
animals, were shown in a previous study [20]. In this study, the loss of
tumor vasculature was related to the property of MMP12 to give origin
Figure 7. Histologic diagnosis of the tumors recovered at autopsy. Tumor slices were stained with hematoxylin-eosin and with Azan-Mallory
stain. Owing to the intense differential dye affinity of breast cancer cells, Matrigel, and necrosis, it was possible to subject stained slices to
image analysis by using a Leica DMR-DC200 light microscope equipped with Leica DC200 digital imaging system (Leica Camera AG) and to
determine the percentage of tumor cells within the tumor mass obtained at autopsy. The figure shows the results obtained with MDA cells.
MCF-7 cells provided similar images. Pictures shown were taken at a magnification of ×40. Experimental conditions are reported on the left
of each line of pictures. The inset in the upper right panel shows the staining affinity of a cell-free Matrigel mass recovered at autopsy.
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to angiostatin by cleavage of plasminogen precursor molecule. Under our
experimental conditions, we did not observe any angiostatin genera-
tion, even in plasminogen-enriched culture medium of breast cancer
cells overproducing MMP12, in line with results previously obtained
in other experimental model systems [21–23]. PTX3 belongs to the
superfamily of “pattern-recognition receptors” involved in innate im-
munity. PTX3 also has an antiangiogenic activity, which has been shown
to depend on its ability to inhibit FGF2 [12,13]. We have shown that,
also under our experimental conditions, PTX3, overproduced by trans-
fected mammary carcinoma cells, inhibits FGF2-dependent stimulation
of capillary morphogenesis by MVEC in vitro. Furthermore, we have
shown that simultaneous use of CM prepared from breast cancer clones
overexpressing MMP12 and PTX3 produced dramatic inhibition of
vascular tube formation both in vitro and in vivo. Interestingly, the
CM of cells overproducing MMP12 also inhibited the proangiogenic
effects of exogenous FGF2 as revealed by capillary morphogenesis ex-
periments. This observation is in line with the reported uPAR require-
ment on endothelial cells stimulated to enter an angiogenic program by
FGF2 [24,25]. One may in fact consider that the uPAR cleavage activ-
ity of MMP12 is equally exerted either on unstimulated or in FGF2-
challenged MVEC. Our data show a weaker effect of PTX3 in vivo with
respect to its activity in vitro. In in vitro experiments, we have observed
that the presence of exogenously added FGF2 fully discloses the anti-
angiogenic activity of PTX3. Therefore, one may reasonably suppose
that the FGF2 concentration within the tumor microenvironment is
not sufficient to make the antiangiogenic activity of PTX3 completely
evident. Finally, the remarkable effect on angiogenesis of the com-
bination of MMP12 and PTX3 is an attractive approach to delivery
in vivo of antiangiogenic genes to improve the treatment outcome in
aggressive tumors. The results of this study suggest that such an ap-
proach may provide a novel strategy for cancer gene therapy by targeting
tumor vasculature.
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